October 1, 2007
By:Joanna Breitstein
You have to admit: Mark McClellan, MD, has quite a resumé. But after you've been the commissioner of FDA and the administrator of the Centers for Medicare and Medicaid Services (CMS), what comes next?
 |
September 1, 2007
By:Louis A. Morris
Many see Vioxx and Avandia as clear signs that the drug safety system has failed. As soon as reports of these drugs' adverse events began to flood the media, consumers—and Congress—demanded to know: "Why didn't we know sooner?"
|
July 30, 2007
By:Richard Altus, ImpactRx
Avandia's market share erosion was magnified further by the almost complete absence of new prescriptions being switched to Avandia from its competitors. In the weeks before the event, Avandia accounted for more than 20 percent of all switches by primary care physicians
|
July 30, 2007
By:Louis A. Morris
A new class of scales that can help capture drug effects—not necessarily disease impacts, as quality-of-life instruments currently do—will likely be needed to identify the meaning of the drug's benefits to patients
|
July 18, 2007
By:Carolynne Van Houten
In the wake of a high-profile death from counterfeit drugs, the industry reacts
|
 | July 3, 2007
By:Louis A. Morris
What's old and established is in, what's new—and once interpreted as"better"—is out
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?